AIM
XLRN

Acrospire Investment Management’s Acceleron Pharma XLRN Stock Holding History

Acrospire Investment Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-350
Closed -$9K – 2667
2017
Q1 		$9K Sell
350
-700
-67% -$18.4K 0.01% 1897
2016
Q4 		$27K Sell
1,050
-700
-40% -$22.2K 0.01% 1678
2016
Q3 		$63K Sell
1,750
-1,500
-46% -$49.7K 0.04% 898
2016
Q2 		$110K Buy
+3,250
New +$106K 0.08% 372

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Acrospire Investment Management's XLRN Position: Q2 2017 in Review

Acrospire Investment Management sold out of Acceleron Pharma (XLRN) in Q2 2017, closing a stake of 350 shares — an estimated $9K sold.

Acrospire Investment Management first reported a position in XLRN in Q2 2016 and held it in 4 quarters. The position peaked at $110K in Q2 2016. 128 funds tracked by Wall St. Rank hold XLRN as of Q2 2017.

  • Acrospire Investment Management reported no remaining Acceleron Pharma position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 350 Acceleron Pharma shares in Q2 2017, an estimated $9K.
  • Acrospire Investment Management first reported a position in Acceleron Pharma in Q2 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Acceleron Pharma position peaked at $110K in Q2 2016.
  • 128 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.